Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2024 call → NO我们只需要根据提供的文本判断是否满足条件。条件要求管理层通过叙述其交易对手(客户、合作伙伴等)自身的扩张来讲述公司未来业务方向,且公司已嵌入其中,且该扩张处于早期且规模大。 在文本中,管理层提到了与Versant Health(MetLife子公司)的合作,说“expanded relationship... will bring an additional 15 million lives in network... nearly double the number of lives within network insurance access with us to over 34 million.” 并且说“Our phased integration began earlier this month and will continue throughout the next couple of quarters.” 这里描述了合作伙伴的扩张(增加覆盖人数),公司已参与其中(integration已开始),且是早期(phased integration刚开始)。但这是否构成“substantial part of management's forward account”?在回答中,管理层确实提到了这个合作,但整体上,管理层更多谈论自己的营销、门店扩张、产品创新等。不过,这个合作是明确的,且描述了对方的规模增长(15 million lives),公司已嵌入(integration开始),且是早期(phases)。但需要看是否“substantial part”以及是否“one coherent posture”中三个条件都满足。 另外,管理层还提到“we continue to see strong adoption of higher priced frames...”,但那是自己的产品。关于保险合作,管理层说“we have not included contribution from this partnership into our guidance”,但描述的是合作伙伴的扩张。然而,这个合作是否构成“the company's own coming volume is presented as a consequence of those parties' own trajectories”?管理层说“we look forward to welcoming lots of new Versant MetLife members to Warby Parker later this year.” 这确实是把未来业务归因于对方的扩张。但整体上,管理层的主要叙述还是自己的行动,比如营销、门店、产品等。而且,这个合作只是众多因素之一,并非“substantial part”。另外,条件要求“one coherent posture”中三个都满足,特别是“the counterparties' trajectory is early and large relative to the company”——这里15 million lives相对于公司现有客户(2.4 million active customers)是大的,但公司说“we have not included contribution from this partnership into our guidance”,说明尚未计入,但描述为未来。然而,这个合作是刚开始的,属于早期。但整体上,管理层并没有把整个前瞻叙述建立在这个合作上,而是主要讲自己的营销和门店扩张。所以,我认为不满足“substantial part”和“one coherent posture”。 另外,还有关于保险的其他部分,但都是泛泛而谈。没有具体描述其他合作伙伴的扩张。因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.